The company
alpha-cannabis Pharma GmbH
In 2017, a multi-member team of experienced specialists from different areas of the pharmaceutical industry founded alpha-cannabis® Pharma GmbH.
In 2018, Organigram Holdings Inc., one of Canada’s leading cannabis companies, joined alpha-cannabis® Pharma GmbH as a shareholder.
With an annual production capacity of up to 100,000kg of medical cannabis flowers, the publicly listed (NASDAQ and TSX) Organigram Holdings Inc. is one of the largest producers of medical cannabis licensed by the Canadian government.
Through this strategic alliance, alpha-cannabis® Pharma GmbH gained a powerful and experienced co-partner and at the same time secured sustainable access to high quality medical cannabis flowers as a source material for its alpha-cannabis® branded products.
In 2018, the company acquired its property in Auetal/Lower Saxony and established a production site there for the GMP-compliant manufacture of pharmaceuticals. Thanks to our own analytics and the equipment with state-of-the-art process engineering facilities, we are able to reliably provide all active ingredients for the entire range of cannabis medicinal products.
As a licensee for the marketing of narcotics and manufacturer cannabis-based medicinal substances, our company is subject to supervision by the BfArM (Federal Institute for Drugs and Medical Devices) and by the Lower Saxony Trade Inspectorate.
alpha-cannabis® Pharma GmbH develops, produces and supplies monograph-compliant cannabis-based active pharmaceutical ingredients (APIs) for therapeutic use. These APIs are exclusively intended for the production of prescription drugs according to medical prescription.
Our qualified and motivated team has an international network with high-performance partners from research, development and industry, which constantly supports us in living up to our own claim: to provide highly effective medical products for therapy as specialists for cannabinoids.